Suraksha Diagnostic Reports 18.83% Y-o-Y Increase in Total Income for Q1 FY26
Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter ended 30th June 2025. The company reported a total income of INR 734.92 million, reflecting a growth of 18.83% compared to the same quarter last year. EBITDA for Q1 FY26 reached INR 246.56 million, marking a 13.51% increase from Q1 FY25. PAT for Q1 FY26 stood at INR 91.75 million, reflecting a growth of 19.67% year-on-year. The company also launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and molecular testing services, and acquired 63% stake in Fetomat Wellness Private Limited. The company expanded its footprint with the addition of three new centres in the quarter.
Key Highlights
- Total Income increased by 18.83% year-on-year for Q1 FY26
- Q1 FY26 EBITDA grew by 13.51% year-on-year
- Q1 FY26 PAT stood at INR 91.75 million, reflecting a growth of 19.67% year-on-year
- Launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and molecular testing services
- Acquired 63% stake in Fetomat Wellness Private Limited